Trial · NCT07235202
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
NCT07235202, Phase 1, Phase 2, Recruiting, Shenzhen Majory Biotechnology Co., Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy. Trials, record NCT07235202. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07235202
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
- NCT number
- NCT07235202
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab-paclitaxel, Gemcitabine (GEM)
- First posted
- 2025-11-19
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants who experience one or more dose-limiting toxicities (DLTs) | Approximately 12 months | |
| Primary | Maximum Tolerated Dose (MTD) of MR001 | Approximately 12 months | The maximum tolerated dose (MTD) of MR001 was assessed for QW dosing schedules |
| Primary | Incidence of Adverse Events (AEs) as Assessed by CTCAE v5.0 | Approximately 30 months | |
| Primary | Objective Response Rate (ORR) | Approximately 24 months | |
| Primary | Best Overall Response (BOR) | Approximately 24 months | |
| Primary | Disease control rate (DCR) | Approximately 24 months | |
| Secondary | Recommended Phase II Dose (RP2D) of MR001 in combination with standard chemotherapy regimens in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) | Approximately 12 months | |
| Secondary | Progressionfree survival (PFS) | Approximately 24 months | |
| Secondary | Overall survival (OS) | Approximately 30 months | |
| Secondary | Area Under the Plasma ConcentrationTime Curve (AUC) of MR001 | Predose and at designated timepoints in each cycle for approximately 18 months (each cycle = 2 weeks or 4 weeks) |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07235202
GET https://conductscience.org/api/trials/v1/NCT07235202/registered